Maxcyte, Inc.
MXCT- Exchange
- Nasdaq
- Industry
- Services-Commercial Physical & Biological Research
- SEC CIK
- 0001287098
In the last 90 days, Maxcyte, Inc. insiders filed 1 open-market purchase and 0 sales; 118 institutions reported holding it in 13F filings for Q3 2026, worth $72.6M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 18, 2026
- $129.1M
- Insider buysLast 90 days, $120.8K in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026, −4 vs. previous quarter
- 118
- 13F valueReported value at the end of Q3 2026
- $72.6M
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $33.0M
- −14.5% year over year
- Net income, FY2025
- -$44.6M
- No comparable prior period
- Free cash flow, FY2025
- -$36.2M
- No comparable prior period
- Revenue, Q3 FY2026
- $10.2M
- +48.7% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $44.6M (135.1% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 1.58M
- Shares sold short
- Change
- −248.6K
- −13.6% vs. previous
- Days to cover
- 1.34
- At average daily volume
Superinvestors holding MXCT, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding MXCT at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Maxcyte, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 18, 2026 (view filing)4:38 PM ET | Nov 17 | 1 day | Masoud MaherPresident and CEO | PPurchase | +100.0K | $1.21 | +$120.8K | +21.1%575.0K after | |
| Mar 19, 2026 (view filing) | Mar 17 | 2 days | Swirsky Douglas JCHIEF FINANCIAL OFFICER | SSale | −10.1K | $0.82 | −$8.32K | −6.3%151.7K after | |
| Aug 27, 2025 (view filing) | Jun 25 | 63 daysLate | Hemrajani RekhaDirector | SSale | −10.7K | $2.09 | −$22.3K | −21.1%39.9K after | 10b5-1 |
| Aug 13, 2025 (view filing) | Aug 13 | Same day | Swirsky Douglas JCHIEF FINANCIAL OFFICER | PPurchase | +50.0K | $1.29 | +$64.5K | +44.7%161.8K after | |
| Aug 13, 2025 (view filing) | Aug 13 | Same day | Masoud MaherPresident and CEO | PPurchase | +75.0K | $1.37 | +$102.8K | +75.0%175.0K after | |
| Aug 13, 2025 (view filing) | Aug 13 | Same day | Erck Stanley CDirector | PPurchase | +100.0K | $1.37 | +$137.0K | +33.5%398.3K after | |
| Aug 13, 2025 (view filing) | Aug 13 | Same day | Douglas RichardDirector | PPurchase | +80.0K | $1.39 | +$111.2K | +53.1%230.6K after | |
| Aug 13, 2025 (view filing) | Aug 13 | Same day | Brooke William WDirector | PPurchase | +50.0K | $1.29 | +$64.5K | +49.6%150.9K after | |
| Mar 20, 2025 (view filing) | Mar 18 | 2 days | Soleymannezhad AliChief Commercial Officer | SSale | −1.21K | $3.18 | −$3.85K | −2.0%59.4K after | |
| Mar 20, 2025 (view filing) | Mar 18 | 2 days | Sandoval David I.GENERAL COUNSEL | SSale | −353 | $3.18 | −$1.12K | −0.5%64.2K after |
Top 10 13F holders, Q3 2026
See all 118 holdersThe largest institutional positions in Maxcyte, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Capricorn Fund Managers Ltd | 8,200,000 | $9.18M | 0.87% | 00.0% | Unchanged |
| Vitruvian Partners LLP | 5,043,356 | $5.65M | 4.99% | 00.0% | Unchanged |
| Liontrust Investment Partners LLP | 4,840,487 | $5.42M | 0.08% | +4,840,487 | New |
| Vanguard Capital Management LLC | 4,008,963 | $4.49M | 0.00% | −22,321−0.6% | Reduced |
| Morgan Stanley | 3,981,178 | $4.46M | 0.00% | +287,129+7.8% | Added |
| BlackRock, Inc. | 3,026,506 | $3.39M | 0.00% | −34,454−1.1% | Reduced |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 2,773,554 | $3.11M | 0.00% | 00.0% | Unchanged |
| Cadian Capital Management, LP | 2,624,685 | $2.94M | 0.25% | +423,519+19.2% | Added |
| Two Sigma Investments, LP | 2,409,859 | $2.70M | 0.00% | +946,918+64.7% | Added |
| Mudita Advisors LLP | 2,260,201 | $2.53M | 0.58% | −1,110,488−32.9% | Reduced |
Holders of 5% or more of MXCT
See all 1 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Maxcyte, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Capricorn Fund Managers Ltd | 13G | 7.70%8.20M shares | New | Feb 5, 20261 filing | Feb 5, 2026 | SEC |